Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain
- PMID: 9384246
- DOI: 10.1016/s0014-2999(97)01255-7
Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain
Abstract
We measured (-)-5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohe xyl]-phenol (CP 55,940)-, (-)11-OH-delta8-tetrahydrocannabinol-dimethylheptyl (HU-210)-, anandamide- and delta9-tetrahydrocannabinol-stimulated G protein activation in mouse brain using the [35S]GTPgammaS functional assay. The Ki values for these drugs were determined by agonist competition binding with the cannabinoid CB1 receptor antagonist [3H]N-(piperidin-1-yl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4- methyl-1H-pyrazole-3-carboxamidehydrochloride ([3H]SR141716A). This information was used to calculate the efficacy for drug stimulation of G protein activity. The rank order of efficacy was CP 55,940 > HU-210 > anandamide > delta9-tetrahydrocannabinol with the latter two drugs being partial agonists. Since efficacy values relate receptor occupancy to functional responses, we believe efficacy values are a better measure of drug-mediated functional responses compared with measurements of drug potency.
Similar articles
-
Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.Eur J Pharmacol. 2003 Jan 10;459(1):83-95. doi: 10.1016/s0014-2999(02)02815-7. Eur J Pharmacol. 2003. PMID: 12505537
-
Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].Biochem Pharmacol. 1996 Mar 8;51(5):669-76. doi: 10.1016/s0006-2952(95)02248-1. Biochem Pharmacol. 1996. PMID: 8615904
-
Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues.Eur J Pharmacol. 2001 Nov 23;431(3):277-86. doi: 10.1016/s0014-2999(01)01438-8. Eur J Pharmacol. 2001. PMID: 11730719
-
Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes.Chem Phys Lipids. 2002 Dec 31;121(1-2):57-63. doi: 10.1016/s0009-3084(02)00146-9. Chem Phys Lipids. 2002. PMID: 12505690 Review.
-
Cannabinoid receptors and their endogenous agonist, anandamide.Neurochem Res. 1998 May;23(5):575-81. doi: 10.1023/a:1022418217479. Neurochem Res. 1998. PMID: 9566594 Review.
Cited by
-
Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.Br J Pharmacol. 2007 Aug;151(7):1041-8. doi: 10.1038/sj.bjp.0707320. Epub 2007 Jun 11. Br J Pharmacol. 2007. PMID: 17558435 Free PMC article.
-
Analgesic Effects and Impairment in Locomotor Activity Induced by Cannabinoid/Opioid Combinations in Rat Models of Chronic Pain.Brain Sci. 2020 Aug 6;10(8):523. doi: 10.3390/brainsci10080523. Brain Sci. 2020. PMID: 32781705 Free PMC article.
-
Effects of cannabinoids on the development of chick embryos in ovo.Sci Rep. 2019 Sep 17;9(1):13486. doi: 10.1038/s41598-019-50004-7. Sci Rep. 2019. PMID: 31530885 Free PMC article.
-
(Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells.Naunyn Schmiedebergs Arch Pharmacol. 2009 Jul;380(1):67-77. doi: 10.1007/s00210-009-0406-z. Epub 2009 Mar 3. Naunyn Schmiedebergs Arch Pharmacol. 2009. PMID: 19255745
-
Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.PLoS One. 2014 Mar 12;9(3):e89566. doi: 10.1371/journal.pone.0089566. eCollection 2014. PLoS One. 2014. PMID: 24622769 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous